SKYE News and Press, Skye Bioscience Inc Com From 03/11/24

2024-03-11 09:29:27 ET More on Skye Bioscience Skye Bioscience announces $50M private placement Seeking Alpha’s Quant Rating on Skye Bioscience Read the full article on Seeking Alpha For further details see: Skye Bioscience looks to raise $40M in a...

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology company focused on the discovery, de...

2024-03-05 13:12:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “How the Medical Industry Could Produce the Biggest AI Stock Winners” was previously published in January 2024. It has since been updated to include the mo...

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with a fo...

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, ...

2024-02-16 09:10:00 ET February 16, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech sector. The newest biotech companies are involved in treatment of heart disease, ...

San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today annou...

2024-01-29 08:25:36 ET More on Skye Bioscience Financial information for Skye Bioscience Read the full article on Seeking Alpha For further details see: Skye Bioscience announces $50M private placement

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience...

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pha...